Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
This study is ongoing, but not recruiting participants.
West Coast Retina Medical Group, Inc.
Information provided by (Responsible Party):
Arthur D. Fu, MD, West Coast Retina Medical Group, Inc.
First received: March 7, 2011
Last updated: February 24, 2012
Last verified: February 2012
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by West Coast Retina Medical Group, Inc.:
Primary Outcome Measures:
- Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment [ Time Frame: This is a one time only blood draw. ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely. [ Time Frame: This is a one time only blood draw and assessment of clinical characteristics. ] [ Designated as safety issue: No ]
|Study Start Date:||April 2011|
|Estimated Study Completion Date:||June 2012|
|Estimated Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
|Wet AMD Non-Responders to Anti-VEGF|
Contacts and Locations